NYC-based Ansel Health Inc. secures $20M in funding. This round was led by Portage, with participation from Two Sigma Ventures, Brewer Lane Ventures, SixThirty Ventures, Plug and Play Ventures, Digitalis Ventures, Symphony AI, Operator Partners, Morgan Creek Capital Management, and several others.
Read also – MA-based 3Daughters Secures Over $2M in Seed Funding
The new infusion of capital, which brings Ansel’s total raised to over $50M, will enable the company to continue to grow the availability of its modern supplemental insurance solution to employees nationwide as per reported by businesswire.com
Ansel’s Founder and CEO, Veer Gidwaney said, “Since launching Ansel in 2019, we’ve made significant progress bringing modern supplemental insurance to more Americans by teaming up with leading insurance carriers and benefits brokerage firms across the country, This financing is an important step towards making health hardships less of a financial burden for Americans nationwide.”
The investment comes on the heels of several important milestones for the company. Last year, Ansel began enabling claims automation, which leverages medical claims data so that members receive benefits without having to file a claim.
Read also – CA-based PowerSchool Acquired Allovue
Ricky Lai, Partner at Portage said, “We believe Ansel’s pioneering approach to supplemental insurance will transform the US health insurance landscape, particularly as the country continues to see growing enrolments into high-deductible health plans. Ansel’s product offers members a more accessible and simplified path to comprehensive healthcare coverage. We are excited to support the team as they enter their next phase of growth,”.
About Ansel
Founded in 2019, Ansel Health Inc. (“Ansel”) is an insurance technology company on a mission to build a world where health hardships don’t create financial hardships. Their new type of supplemental health insurance plan covers 13,000+ conditions and pays cash benefits upon diagnosis of a covered condition with no accident or hospitalization requirements.
Read also – R.I.-based Bolden Therapeutics, Inc. Secures $1.5M in Pre-Seed Convertible Note Funding
